{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T09:43:42Z","timestamp":1793785422916,"version":"4.6.1"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:p>Treatment for advanced melanoma after progression on immunotherapy is limited. This phase II trial (NCT03422445) was conducted to evaluate the efficacy and safety of apatinib plus temozolomide in patients with advanced melanoma after failure of immunotherapy. Patients with unresectable stage III or stage IV melanoma after progression on immunotherapy were treated with temozolomide 300 mg on days 1\u20135 and apatinib 500 mg daily every 28-day cycle until disease progression or intolerable toxicities. Besides immunotherapy, prior chemotherapy, targeted therapy, and clinical trials were allowed. The primary endpoint was progression-free survival. Secondary endpoints were objective response rate, disease control rate, overall survival, and safety. Of 29 patients, 28 (96.6%) had metastatic diseases, and the predominant subtypes were mucosal [12 (41.4%)] and acral melanoma [eight (27.6%)]. Five (17.2%) patients showed BRAF, CKIT, or NRAS mutation. Five achieved confirmed partial response, with an objective response rate of 17.2%. The disease control rate was 82.8%. The median progression-free survival was 5.0 months [95% confidence interval (CI): 4.7\u20135.3], and the median overall survival was 10.1 months (95% CI: 5.1\u201315.0). Grade 3\u20134 treatment-related adverse events included proteinuria [four (13.8%)], thrombocytopenia [two (6.9%)], hypertension [one (3.4%)], and hyperbilirubinemia [one (3.4%)]. No treatment-related death occurred. Apatinib plus temozolomide demonstrated promising efficacy and manageable safety profile in patients with advanced melanoma after progression on immunotherapy.<\/jats:p>","DOI":"10.1097\/cmr.0000000000000809","type":"journal-article","created":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T08:00:24Z","timestamp":1645516824000},"page":"142-149","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Phase II study of apatinib combined with temozolomide in patients with advanced melanoma after failure of immunotherapy"],"prefix":"10.1097","volume":"32","author":[{"given":"Li","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Si","sequence":"additional","affiliation":[{"name":"Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Chi","sequence":"additional","affiliation":[{"name":"Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinan","family":"Sheng","sequence":"additional","affiliation":[{"name":"Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Lian","sequence":"additional","affiliation":[{"name":"Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bixia","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xieqiao","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siming","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanliang","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,2,20]]},"reference":[{"key":"R1-20250528","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1200\/JCO.20.00198","article-title":"Systemic therapy for melanoma: ASCO guideline.","volume":"38","author":"Seth","year":"2020","journal-title":"J Clin Oncol"},{"key":"R2-20250528","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma.","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"R3-20250528","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2217\/imt-2018-0208","article-title":"Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison.","volume":"11","author":"Atkins","year":"2019","journal-title":"Immunotherapy"},{"key":"R4-20250528","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/s41591-019-0476-5","article-title":"Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.","volume":"25","author":"Ribas","year":"2019","journal-title":"Nat Med"},{"issue":"36_suppl","key":"R5-20250528","doi-asserted-by":"crossref","first-page":"356154","DOI":"10.1200\/JCO.2021.39.36_suppl.356154","article-title":"DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing): a phase III trial\u2014ECOG-ACRIN EA6134.","volume":"39","author":"Atkins","year":"2021","journal-title":"J Clin Oncol"},{"key":"R6-20250528","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/annonc\/mdz011","article-title":"Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.","volume":"30","author":"Hamid","year":"2019","journal-title":"Ann Oncol"},{"key":"R7-20250528","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma.","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"R8-20250528","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejca.2017.01.009","article-title":"Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.","volume":"75","author":"Zimmer","year":"2017","journal-title":"Eur J Cancer"},{"key":"R9-20250528","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1093\/annonc\/mdz398","article-title":"Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis.","volume":"30","author":"Dafni","year":"2019","journal-title":"Ann Oncol"},{"key":"R10-20250528","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1126\/science.abb5920","article-title":"Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients.","volume":"371","author":"Baruch","year":"2021","journal-title":"Science"},{"key":"R11-20250528","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/cam4.2110","article-title":"Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma.","volume":"8","author":"Fujisawa","year":"2019","journal-title":"Cancer Med"},{"key":"R12-20250528","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1471-2407-11-85","article-title":"Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases.","volume":"11","author":"Chi","year":"2011","journal-title":"BMC Cancer"},{"key":"R13-20250528","first-page":"1005","article-title":"Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification.","volume":"28","author":"Rastrelli","year":"2014","journal-title":"In Vivo"},{"key":"R14-20250528","first-page":"e23","article-title":"Mucosal melanoma: new insights and therapeutic options for a unique and aggressive disease.","volume":"31","author":"Lerner","year":"2017","journal-title":"Oncology (Williston Park)"},{"key":"R15-20250528","doi-asserted-by":"crossref","first-page":"942","DOI":"10.2214\/AJR.16.16800","article-title":"Clinical and imaging features of noncutaneous melanoma.","volume":"208","author":"Wong","year":"2017","journal-title":"AJR Am J Roentgenol"},{"key":"R16-20250528","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.tranon.2019.02.007","article-title":"A phase Ib study of pembrolizumab as second-line therapy for Chinese patients with advanced or metastatic melanoma (KEYNOTE-151).","volume":"12","author":"Si","year":"2019","journal-title":"Transl Oncol"},{"key":"R17-20250528","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1200\/JCO.19.00210","article-title":"Axitinib in combination with toripalimab, a humanized immunoglobulin G4 monoclonal antibody against programmed cell death-1, in patients with metastatic mucosal melanoma: an open-label phase IB trial.","volume":"37","author":"Sheng","year":"2019","journal-title":"J Clin Oncol"},{"key":"R18-20250528","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13045-018-0693-2","article-title":"Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients.","volume":"12","author":"Tang","year":"2019","journal-title":"J Hematol Oncol"},{"key":"R19-20250528","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.hoc.2009.03.006","article-title":"The history and future of chemotherapy for melanoma.","volume":"23","author":"Yang","year":"2009","journal-title":"Hematol Oncol Clin North Am"},{"key":"R20-20250528","doi-asserted-by":"crossref","first-page":"100949","DOI":"10.1016\/j.tranon.2020.100949","article-title":"Chemotherapy combined with antiangiogenic drugs as salvage therapy in advanced melanoma patients progressing on PD-1 immunotherapy.","volume":"14","author":"Wang","year":"2021","journal-title":"Transl Oncol"},{"key":"R21-20250528","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.tranon.2018.07.009","article-title":"Safety and efficacy of apatinib combined with temozolomide in advanced melanoma patients after conventional treatment failure.","volume":"11","author":"Cui","year":"2018","journal-title":"Transl Oncol"},{"key":"R22-20250528","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41525-021-00169-w","article-title":"Ratio of the interferon-\u03b3 signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma.","volume":"6","author":"Cui","year":"2021","journal-title":"NPJ Genom Med"},{"key":"R23-20250528","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1200\/JCO.2000.18.1.158","article-title":"Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.","volume":"18","author":"Middleton","year":"2000","journal-title":"J Clin Oncol"},{"key":"R24-20250528","doi-asserted-by":"crossref","first-page":"e0212513","DOI":"10.1371\/journal.pone.0212513","article-title":"Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway.","volume":"14","author":"Kato","year":"2019","journal-title":"PLoS One"},{"key":"R25-20250528","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.19.01598","article-title":"Phase IB\/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors.","volume":"38","author":"Taylor","year":"2020","journal-title":"J Clin Oncol"},{"key":"R26-20250528","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/j.bbrc.2017.12.032","article-title":"Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3.","volume":"495","author":"Zheng","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"R27-20250528","doi-asserted-by":"crossref","first-page":"5333","DOI":"10.2147\/OTT.S175507","article-title":"Apatinib mesylate tablet in the treatment of advanced malignant melanoma.","volume":"11","author":"Yang","year":"2018","journal-title":"Onco Targets Ther"}],"container-title":["Melanoma Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CMR.0000000000000809","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T21:45:27Z","timestamp":1748468727000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CMR.0000000000000809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,20]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/cmr.0000000000000809","relation":{},"ISSN":["0960-8931"],"issn-type":[{"value":"0960-8931","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2,20]]}}}